Maternal ADHD and Perinatal Prescription Stimulant Use.
ADHD
Truven MarketScan®
in utero exposure
maternal health
mental health
pregnancy
pregnancy complications
stimulants
Journal
Journal of attention disorders
ISSN: 1557-1246
Titre abrégé: J Atten Disord
Pays: United States
ID NLM: 9615686
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
21
1
2022
medline:
24
6
2022
entrez:
20
1
2022
Statut:
ppublish
Résumé
To describe patterns and predictors of perinatal prescription stimulant use. We used MarketScan Out of 612,001 pregnancies, 15,413 involved pre-pregnancy stimulant use. Of these, stimulant treatment was discontinued prior to conception in 6,416 (42%), discontinued during trimester 1 in 5,977 (39%), and continued into later trimesters in 3,020 (19%). Compared with pregnancies involving stimulant discontinuation prior to conception, those that continued into pregnancy occurred in women who were older (29.9 vs. 28.9 years) and had more severe ADHD (3.1 vs. 1.8 ADHD-related billing claims). There is considerable heterogeneity in the management of ADHD during pregnancy.
Identifiants
pubmed: 35048729
doi: 10.1177/10870547211073472
doi:
Substances chimiques
Central Nervous System Stimulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM